Full Press Release Details
QED Therapeutics Presents Data For Infigratinib In Cholangiocarcinoma In Late Breaking Abstract At The European Society Of Medical Oncology 2018 Congress.
BBIO
QED Therapeutics Presents Data For Infigratinib In Cholangiocarcinoma In Late Breaking Abstract At The European Society Of Medical Oncology 2018 Congress
Key Takeaway: QED Therapeutics Presents Data For Infigratinib In Cholangiocarcinoma In Late Breaking Abstract At The European Society Of Medical Oncology 2018 Congress
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis